Core Viewpoint - Premier American Uranium Inc. is advancing its Cebolleta Uranium Project in New Mexico with a 2026 work program aimed at optimizing uranium recovery through heap leaching, following a promising 2025 Preliminary Economic Assessment (PEA) that highlighted significant potential for value enhancement through improved metallurgical recovery [1][6]. Work Program Details - The 2026 work program has a budget of US$1.1 million and focuses on bulk sampling, targeted drilling, and comprehensive metallurgical testing to optimize recovery assumptions from the 2025 PEA [2]. - The program will be led by Dr. Terry McNulty, a renowned metallurgical engineer, with testing conducted at Hazen Research, Inc., a leading independent laboratory [3]. Metallurgical Testing and Recovery Potential - The 2025 PEA indicated that a 12.5% increase in metallurgical recovery could lead to a US$75 million increase in after-tax net present value (NPV), highlighting the project's sensitivity to recovery rates [6][7]. - The 2025 PEA assumed a base-case metallurgical recovery of 80%, with sensitivity analysis showing that increasing recovery to 90% could raise the after-tax NPV from US$84 million to US$159 million [7][9]. Project Overview - The Cebolleta Uranium Project is positioned as one of the largest advanced uranium projects in the U.S., with a potential mine life of 13 years and an average annual production of 1.4 million pounds of U₃O₈, peaking at 2.0 million pounds [9][11]. - The project is strategically located in a premier uranium district, benefiting from proximity to utilities and existing processing facilities [11]. Financial Metrics from 2025 PEA - The 2025 PEA outlines an after-tax NPV of US$83.9 million at a base case uranium price of US$90 per pound, with an after-tax internal rate of return (IRR) of 17.7% and projected life-of-mine after-tax free cash flow of US$287 million [9]. - The study also indicates strong leverage to uranium prices, with NPV increasing significantly at higher price points [9]. Company Background - Premier American Uranium is focused on consolidating and developing uranium projects across the U.S. to enhance domestic energy security and support the transition to clean energy [19][20]. - The company has a strong financial backing and a distinguished team with expertise in uranium exploration and development [20].

Core Insights - Radiopharm Theranostics has initiated its first-in-human Phase 1 clinical trial of RAD 402, a monoclonal antibody targeting KLK3 for advanced prostate cancer [1][3] - The trial aims to evaluate the safety, tolerability, and preliminary clinical activity of RAD 402, with a focus on determining the Maximum Tolerated Dose (MTD) and/or recommended phase 2 dose (RP2D) [2] Group 1: Product Development - RAD 402 is designed to selectively target KLK3-expressing tumors while minimizing off-target exposure, demonstrating strong tumor uptake and minimal bone or marrow involvement in preclinical studies [3][4] - The preclinical proof-of-concept studies showed a hepatic excretion profile consistent with expectations for a monoclonal antibody, indicating a favorable biodistribution [4] Group 2: Company Overview - Radiopharm Theranostics is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for high unmet medical needs, listed on ASX (RAD) and NASDAQ (RADX) [5] - The company has a diverse pipeline that includes one Phase 2 and four Phase 1 trials targeting various solid tumors, including lung, breast, prostate, and brain metastases [5]

Core Insights - Legence Corp. reported record quarterly revenues of $737.6 million for Q4 2025, marking a 34.6% increase from $548.2 million in Q4 2024, primarily driven by organic growth [1][4][3] - The company achieved a record total backlog and awarded contracts of $3.7 billion, a 49% increase year-over-year, with a robust book-to-bill ratio of 1.9x for Q4 [1][24][25] - Non-GAAP Adjusted EBITDA for Q4 2025 was $87.0 million, reflecting a 53.2% increase from $56.8 million in Q4 2024 [4][3] Financial Performance - Q4 2025 revenues totaled $737.6 million, up 34.6% from $548.2 million in Q4 2024 [4][5] - Gross profit for Q4 2025 was $147.5 million, with a gross margin of 20.0%, compared to $112.9 million and 20.6% in Q4 2024 [4][5] - For the full year 2025, total revenues reached $2.6 billion, a 21.5% increase from $2.1 billion in 2024 [5][8] Segment Performance - The Engineering & Consulting segment generated $172.6 million in revenue for Q4 2025, a 10.0% increase from $156.9 million in Q4 2024, driven by demand for Program & Project Management services [9][12] - The Installation & Maintenance segment reported revenues of $565.1 million for Q4 2025, a 44.4% increase from $391.3 million in Q4 2024, primarily due to strong demand from data centers and life sciences clients [16][18] - For the full year 2025, the Installation & Maintenance segment revenues totaled $1.8 billion, up 21.9% from $1.5 billion in 2024 [22][23] Backlog and Contracts - Total backlog and awarded contracts reached $3.7 billion as of December 31, 2025, a 48.6% increase from $2.5 billion a year earlier [24][26] - The Engineering & Consulting segment backlog increased by 16.2% year-over-year, while the Installation & Maintenance segment backlog surged by 65.8% [24][25] Acquisitions - On March 1, 2026, Legence completed the acquisition of Metrix Engineers LLC for approximately $30 million, enhancing its engineering capabilities in the Pacific Northwest [27][28] - The company also acquired Bowers on January 2, 2026, for an upfront cash payment of $325 million, funded through a combination of cash and debt [29] Guidance - For Q1 2026, Legence expects revenues between $925 million and $950 million, with Non-GAAP Adjusted EBITDA projected at $90 million to $100 million [30][31] - The full-year 2026 guidance has been raised to revenues of $3.7 billion to $3.9 billion and Non-GAAP Adjusted EBITDA of $400 million to $430 million [34]

Core Viewpoint - DoubleDown Interactive Co., Ltd. held its annual general meeting on March 27, 2026, where shareholders approved several key resolutions regarding the company's governance and financial statements [1]. Group 1: Company Overview - DoubleDown Interactive is a leading developer and publisher of digital games, focusing on mobile and web-based platforms, and aims to provide authentic Vegas entertainment through online social casino experiences [2]. - The flagship product, DoubleDown Casino, has been popular among casual players, entertaining millions globally with a variety of classic and modern games [2]. - The company also operates through its subsidiary SuprNation, which runs three real-money iGaming sites in Western Europe, and the newly acquired WHOW Games, which focuses on social casino gaming in Europe, particularly in Germany [2]. Group 2: Shareholder Meeting Resolutions - The shareholders approved the 18th financial statements and consolidated financial statements for the fiscal year ended December 31, 2025 [3]. - Two Independent Directors, Sung Uk Park and Il Jin Park, were elected [3]. - A partial amendment to the Articles of Incorporation was approved [3]. - The remuneration limit for Independent Directors and Executive Officers was also approved [3].

Core Insights - Humacyte, Inc. reported total revenues of $0.5 million for Q4 2025 and $2.0 million for the full year, with significant growth in product sales and collaborations [1][11] - The company received a purchase commitment of $1.475 million for a clinical evaluation program in Saudi Arabia, indicating strong international interest in its product, Symvess [1][4] - A Marketing Authorization Application for Symvess has been submitted to the Israel Ministry of Health, expanding its market reach [1][5] - The U.S. Department of Defense has authorized funding for the procurement of bioengineered blood vessels, highlighting the product's relevance for military applications [1][4] - An important milestone is expected in Q2 2026 with the announcement of top-line interim results from the V012 Phase 3 study in hemodialysis access [1][3] Financial Performance - Revenue for Q4 2025 was $0.5 million, with $0.4 million from U.S. sales of 25 Symvess units and $0.1 million from a research collaboration [11][29] - For the full year 2025, revenue totaled $2.0 million, with $1.4 million from U.S. sales of 61 Symvess units and $0.6 million from research collaborations [11][29] - Cost of goods sold was $9.1 million for Q4 2025 and $9.7 million for the full year, including an $8.9 million inventory reserve [11][29] - Research and development expenses decreased to $14.6 million in Q4 2025 from $20.7 million in Q4 2024, reflecting a shift towards commercial operations [11][29] - The net loss for Q4 2025 was $24.8 million, compared to a net loss of $20.9 million in Q4 2024, while the annual net loss decreased to $40.8 million from $148.7 million [11][29] Product Development and Pipeline - The company is advancing its coronary tissue engineered vessel (CTEV) towards a first-in-human study in CABG, with plans to initiate clinical trials in the second half of 2026 [3][8] - The V012 Phase 3 study is designed to assess the efficacy and safety of the acellular tissue engineered vessel (ATEV) for hemodialysis, with interim results expected by early June 2026 [9][11] - Long-term efficacy and safety data for Symvess have been published, demonstrating its durability and low infection rates in various applications [9][11] Market Expansion - Humacyte is actively expanding the commercialization of Symvess in international markets, with a focus on education and evaluation programs for surgeons in Saudi Arabia [3][4] - The company has received multiple Value Analysis Committee (VAC) approvals, with 27 hospitals having ordered Symvess, indicating growing acceptance in the U.S. market [4][11]

Core Viewpoint - Tulikivi Corporation has released its annual report for 2025, which includes financial statements, auditor's report, Board of Directors' report, corporate governance statement, and remuneration report [1]. Group 1: Financial Reporting - The financial statements for 2025 have been published in XHTML format, compliant with the European Single Electronic Format (ESEF) reporting requirements [1]. - The main statements in the consolidated financial statements and the notes have been tagged with XBRL as per ESEF requirements [1]. - An auditor has submitted a certification report on the ESEF financial statements [1]. Group 2: Accessibility - The financial statements are appended to the bulletin in XHTML format and the annual report is available as a PDF file [1]. - These documents can also be accessed on the company's website at www.tulikivigroup.com [1].

Core Insights - 2025 was a pivotal year for Satellos Bioscience, marked by significant advancements in clinical programs, including the initiation of two Phase 2 trials for SAT-3247 targeting Duchenne muscular dystrophy (DMD) [2] - The company is optimistic about the potential of SAT-3247 as a disease-modifying therapy, with ongoing trials expected to yield meaningful clinical updates in 2026 [2] Clinical Progress - SAT-3247 is an oral small-molecule tablet aimed at restoring muscle regeneration by addressing deficits in muscle stem cell polarity in DMD and potentially other muscle diseases [3] - BASECAMP is a Phase 2 pediatric study involving 51 children aged 7 to under 10 years, evaluating the safety and treatment effect of SAT-3247 over three months [4] - TRAILHEAD is a 12-month open-label Phase 2 study assessing long-term safety and efficacy of SAT-3247 in adults with DMD [4] Financial Highlights - As of December 31, 2025, Satellos reported cash and cash equivalents of $27.7 million, down from $48.5 million in 2024, primarily due to clinical trial costs [9] - The company reported a net loss of $24.9 million for 2025, compared to a net loss of $20.6 million in 2024, attributed to increased R&D expenses related to clinical activities [10] - R&D expenses rose to $18.4 million in 2025 from $14.4 million in 2024, reflecting costs associated with the Phase 2 trial initiation [13] Corporate Achievements - Satellos completed a $57.2 million equity financing and began trading on the Nasdaq Global Market under the ticker "MSLE" on February 6, 2026 [5][12] - The company appointed new executives to strengthen its clinical development and regulatory strategy [12] Research and Development - New preclinical data presented at the MDA conference indicated significant muscle strength enhancement in the FLEX DUX4 model of facioscapulohumeral muscular dystrophy (FSHD), supporting the potential expansion of SAT-3247 beyond DMD [7] - A novel Regenerative Index (RI) methodology was validated, which may serve as a biomarker for evaluating muscle regeneration and treatment effects [6][9]

Core Viewpoint - Orvana Minerals Corp. has successfully upgraded to trade on the OTCQX Best Market, enhancing its visibility and accessibility to U.S. investors [1][4]. Company Overview - Orvana Minerals Corp. is a multi-mine gold-copper-silver company with operations in Spain, Bolivia, and Argentina [5]. - The company operates the Orovalle mine in Spain, the Don Mario mine in Bolivia, and the Taguas property in Argentina [5]. Market Upgrade Significance - Upgrading to the OTCQX Market allows for transparent trading for U.S. investors and enables companies listed on qualified international exchanges to utilize their home market reporting [3]. - Companies must meet high financial standards, adhere to best practice corporate governance, and comply with applicable securities laws to qualify for OTCQX [3]. Strategic Goals - The upgrade is part of Orvana's strategy to expand its investor base and support its growth strategy, which includes restarting production in Bolivia, advancing exploration in Argentina, and maintaining stable operations in Spain [4].

Core Viewpoint - Werewolf Therapeutics is exploring various strategic options to maximize shareholder value, including potential sale, merger, or collaboration arrangements [2]. Financial Results - As of December 31, 2025, cash and cash equivalents were $57.1 million, down from $65.7 million as of September 30, 2025, which is expected to fund operations into Q4 2026 [5]. - Research and development expenses for Q4 2025 were $6.9 million, a decrease from $15.7 million in Q4 2024; total R&D expenses for 2025 were $44.8 million, down from $56.4 million in 2024 [5]. - General and administrative expenses for Q4 2025 were $2.5 million, compared to $4.6 million in Q4 2024; total G&A expenses for 2025 were $15.8 million, down from $19.0 million in 2024 [5]. - The net loss for Q4 2025 was $8.4 million, significantly reduced from $20.4 million in Q4 2024; the total net loss for 2025 was $60.8 million, compared to $70.5 million in 2024 [5]. Company Overview - Werewolf Therapeutics is focused on developing conditionally activated therapeutics to stimulate the immune system for cancer and other immune-mediated conditions, utilizing its proprietary PREDATOR platform [4]. - The company's advanced clinical-stage candidates include WTX-124 and WTX-330, which are designed to treat solid tumors through conditionally activated Interleukin-2 and Interleukin-12 molecules [4].

Core Viewpoint - The company ADMA Biologics refutes allegations made by short seller Culper Research regarding its immune globulin product ASCENIV, emphasizing that demand and utilization have steadily increased over the past two years, reaching record levels [1][2]. Group 1: Demand and Utilization - Demand for ASCENIV has shown significant growth, with data from distribution partners indicating an increase in end-user demand over the past two-plus years [5]. - As of January 5, 2026, and March 22, 2026, average inventory days on hand for ASCENIV were reported at 84 and 48 days, respectively, exceeding the distributors' minimum requirements [7]. - The company maintains that its distributors stock above the minimum levels to ensure continuity of care for immune-compromised patients who require therapy every 21-28 days [6]. Group 2: Inventory Management - Inventory levels for ASCENIV and BIVIGAM are consistent with industry standards, with average days of inventory on hand reported at 128 and 90 days for ASCENIV as of January 5, 2026, and March 22, 2026, respectively [10]. - The company asserts that these inventory levels are appropriately sized to ensure proper handling and mitigate potential supply chain disruptions [10]. Group 3: Competitive Positioning - ASCENIV is positioned as a late-line therapy for immune-compromised individuals who do not respond to standard immunoglobulin treatments, allowing it to command premium pricing [15]. - The short report's claims regarding competitive pressure from new immune globulin product launches are described as misguided by the company [15][13]. Group 4: Financial Integrity - ADMA has received unqualified opinions in its audits for FY 2024 and FY 2025, confirming the effectiveness of its internal controls over financial reporting [14]. - The company has filed its Annual Reports on Form 10-K for the years ended December 31, 2024, and 2025, with no undisclosed related party transactions reported [15].